BCAT2 and urinary bladder cancer: Further, the outcomes of comprehensive pan‐cancer analysis on chemokine system, MHCs, immunostimulators and TIICs indicated that BCAT2 has significant immunosuppressive effects in a couple of cancer types, including bladder cancer (BLCA), breast cancer (BRCA), kidney renal papillary cell carcinoma (KIRP), pancreatic adenocarcinoma (PAAD), sarcoma (SARC) and thyroid carcinoma (THCA) (Figure S2A,B, Supporting Information).